Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone
Introduction: An increased risk of developing vitiligo has recently been described in patients with atopic dermatitis (AD). Vitiligo and AD can be associated because of shared pathogenetic pathways, including alterations in the Janus kinases/signal transducer and activator of transcriptio...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-02-01
|
| Series: | Case Reports in Dermatology |
| Online Access: | https://karger.com/article/doi/10.1159/000544703 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133578633969664 |
|---|---|
| author | Lina Maria Magnanimi Andrea De Berardinis Maria Esposito Maria Concetta Fargnoli |
| author_facet | Lina Maria Magnanimi Andrea De Berardinis Maria Esposito Maria Concetta Fargnoli |
| author_sort | Lina Maria Magnanimi |
| collection | DOAJ |
| description |
Introduction: An increased risk of developing vitiligo has recently been described in patients with atopic dermatitis (AD). Vitiligo and AD can be associated because of shared pathogenetic pathways, including alterations in the Janus kinases/signal transducer and activator of transcription (JAK/STAT) signaling, suggesting JAK inhibitors as a promising new therapeutic approach in vitiligo. Case Presentation: We describe a 25-year-old woman diagnosed with AD since childhood and subsequent onset of slowly progressive vitiligo at the age of 16. Systemic therapy with JAK1 inhibitor upadacitinib 15 mg daily was started, after a medical and laboratory evaluation to exclude pregnancy and other contraindications. Progressive improvement of AD was observed after the first weeks of treatment with clinical remission at week 16. At the same time, clear improvement of vitiligo was observed with an almost complete remission achieved at week 28 of treatment. Conclusion: The remission of both AD and vitiligo achieved with upadacitinib monotherapy supports the therapeutic utility of inhibition of JAK 1 signaling in these patients. |
| format | Article |
| id | doaj-art-4054396f511f4e55bc285e7b4753fd03 |
| institution | OA Journals |
| issn | 1662-6567 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Dermatology |
| spelling | doaj-art-4054396f511f4e55bc285e7b4753fd032025-08-20T02:31:56ZengKarger PublishersCase Reports in Dermatology1662-65672025-02-01171919510.1159/000544703Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One StoneLina Maria MagnanimiAndrea De BerardinisMaria EspositoMaria Concetta Fargnoli Introduction: An increased risk of developing vitiligo has recently been described in patients with atopic dermatitis (AD). Vitiligo and AD can be associated because of shared pathogenetic pathways, including alterations in the Janus kinases/signal transducer and activator of transcription (JAK/STAT) signaling, suggesting JAK inhibitors as a promising new therapeutic approach in vitiligo. Case Presentation: We describe a 25-year-old woman diagnosed with AD since childhood and subsequent onset of slowly progressive vitiligo at the age of 16. Systemic therapy with JAK1 inhibitor upadacitinib 15 mg daily was started, after a medical and laboratory evaluation to exclude pregnancy and other contraindications. Progressive improvement of AD was observed after the first weeks of treatment with clinical remission at week 16. At the same time, clear improvement of vitiligo was observed with an almost complete remission achieved at week 28 of treatment. Conclusion: The remission of both AD and vitiligo achieved with upadacitinib monotherapy supports the therapeutic utility of inhibition of JAK 1 signaling in these patients. https://karger.com/article/doi/10.1159/000544703 |
| spellingShingle | Lina Maria Magnanimi Andrea De Berardinis Maria Esposito Maria Concetta Fargnoli Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone Case Reports in Dermatology |
| title | Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone |
| title_full | Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone |
| title_fullStr | Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone |
| title_full_unstemmed | Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone |
| title_short | Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone |
| title_sort | upadacitinib monotherapy in vitiligo associated with atopic dermatitis killing two birds with one stone |
| url | https://karger.com/article/doi/10.1159/000544703 |
| work_keys_str_mv | AT linamariamagnanimi upadacitinibmonotherapyinvitiligoassociatedwithatopicdermatitiskillingtwobirdswithonestone AT andreadeberardinis upadacitinibmonotherapyinvitiligoassociatedwithatopicdermatitiskillingtwobirdswithonestone AT mariaesposito upadacitinibmonotherapyinvitiligoassociatedwithatopicdermatitiskillingtwobirdswithonestone AT mariaconcettafargnoli upadacitinibmonotherapyinvitiligoassociatedwithatopicdermatitiskillingtwobirdswithonestone |